ArriVent BioPharma Balance Sheet Health
Financial Health criteria checks 5/6
ArriVent BioPharma has a total shareholder equity of $277.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $292.7M and $15.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$282.86m |
| Equity | US$277.49m |
| Total liabilities | US$15.22m |
| Total assets | US$292.71m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AVBP's short term assets ($292.4M) exceed its short term liabilities ($15.2M).
Long Term Liabilities: AVBP's short term assets ($292.4M) exceed its long term liabilities ($56.0K).
Debt to Equity History and Analysis
Debt Level: AVBP is debt free.
Reducing Debt: AVBP had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVBP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AVBP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.